Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Revuforj ® (revumenib) was named Best New Drug at the ...
In patients with coronary artery disease (CAD) and obesity, tirzepatide was associated with lower mortality and reduced ...
This study retrospectively analyzed ten pediatric patients with HOX-driven AML who received revumenib maintenance after HSCT at a single-center. The median age was 10 years (range: 1-18). 80% (8/10) ...
The FDA has granted standard approval to rucaparib (Rubraca) for the treatment of patients with metastatic ...
Malar edema, the collection of fluid below the infraorbital rim and over the malar eminence, presents a unique challenge to ...
Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj), the first and only subcutaneously (SC) ...
The FDA has approved an oral pellet formulation of Orladeyo® to prevent attacks of hereditary angioedema in pediatric patients.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase ...
Depemokimab-ulaa (Exdensur) is approved for severe asthma with an eosinophilic phenotype, offering protection with just two ...
High-altitude mountains offer breathtaking views but can also cause altitude sickness if you don’t rest; doctor explains symptoms and management tips ...
An unusually high number of people developed a heart attack, lung complication or general illness within 90 days after the ...
The FDA has approved Exdensur for add-on maintenance treatment of severe asthma characterized by an eosinophilic phenotype in patients aged 12 and older.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results